Cytokine Release Syndrome (CRS) — The Main CAR-T Complication

Cytokine release syndrome is a whole-body inflammatory reaction. It happens when reprogrammed CAR-T cells find their target, switch on and multiply, releasing signalling proteins called cytokines into the blood. Those cytokines cause fever, and sometimes low blood pressure and breathlessness. It is the most common serious complication of CAR-T cell therapy.

Cytokines are messengers, not poison. They are the proteins immune cells use to call each other into action. CRS is what happens when a very large number of newly activated cells send that message at once. The reaction is the immune system working hard, in the wrong gear.

If someone has had a CAR-T infusion and their temperature is rising, call the treating centre’s 24-hour number now. Do not wait for morning. Do not bring the fever down with paracetamol first and then decide. Do not go to a general clinic that does not know cell therapy has been given. A fever after CAR-T is treated as CRS until the centre proves otherwise, and the medicines that control it are kept at that centre.

Said plainly: CION Cancer Clinics does not provide CAR-T or any other cell therapy, and does not manage CRS after an infusion. This page exists so families can understand what has been described to them, and so we can point you to the right specialist centre if your diagnosis is one where CAR-T is genuinely discussed.

Timing bands follow the patterns described in ASCO and NCCN guidance on CAR-T-cell therapy toxicity. They describe typical patterns rather than fixed rules, and vary between products and between people. Ask your centre for its own written monitoring window and keep it on the fridge.

Grading follows the ASTCT consensus criteria used internationally and reflected in ASCO and NCCN toxicity guidance. The grade is assigned by the treating team, reviewed hour by hour, and moves in both directions as the patient responds.

1. 1

   The fever is reported immediately

   Any temperature after infusion goes straight to the treating team. Blood cultures are taken at the same moment, because early CRS and early infection are indistinguishable.

2. 2

   The reaction is graded

   Temperature, blood pressure and oxygen are measured repeatedly and a grade from 1 to 4 is assigned. The grade decides what is given next, not how alarming the room feels.

3. 3

   Supportive care comes first

   Fluids to hold blood pressure, oxygen if it is needed, paracetamol for the fever, and antibiotics until infection is ruled out. Grade 1 CRS is often no more than this.

4. 4

   An interleukin-6 blocking antibody

   For moderate or worse CRS, centres give an antibody that blocks interleukin-6 signalling. Holding stock of it on site is a condition of being allowed to infuse CAR-T at all.

5. 5

   Corticosteroids where the reaction persists

   Steroids are added when the reaction does not settle, or when neurological effects appear alongside it. Dose and duration are decided by the treating team, case by case.

6. 6

   Intensive care for severe reactions

   Grade 3 and grade 4 CRS is managed with blood-pressure support and, at the extreme, ventilation. This capability is why only a handful of accredited centres may deliver CAR-T.

7. 7

   The watch continues after CRS settles

   Attention then turns to neurological effects, blood counts that can stay low for weeks, and infection risk. Discharge from the CRS window is not discharge from monitoring.

Management steps follow ASCO and NCCN guidance on CAR-T-cell therapy toxicity, written for general understanding. They describe what a centre does, not what anyone should attempt at home. There is no home management of CRS.

• Who answers at 2am? — Ask for the 24-hour number in writing, and who picks it up. Fever does not keep office hours.
• How close must we stay, and for how long? — Centres set a distance and a duration. Ask before booking accommodation, not after.
• Is the CRS medicine on site for us? — Accredited centres hold an interleukin-6 blocking antibody in stock. Ask them to confirm it is there.
• What happens if the ICU is full? — Grade 3 or 4 CRS needs intensive care at short notice. Ask what the plan is when beds are tight.
• What is in the written estimate? — Ask for the product, the hospital stay, ICU days and the toxicity medicines listed separately. Any figure quoted anywhere should be read as indicative, as of August 2026.
• What if the batch fails or the disease progresses while we wait? — Both happen. Ask what the fallback plan is before you need one.

Immunotherapy of every kind attracts confident promises. Nobody, at any centre, can tell you in advance whether CAR-T will work for you, and nobody should describe the result as certain. Ask instead for a realistic written picture for your specific case, and take it to a second opinion.

No. CION Cancer Clinics does not administer, stock or manufacture CAR-T cell therapy or any other cell therapy, and does not manage cytokine release syndrome after an infusion. That care belongs to the accredited centre that gave the cells, and their emergency number is the one to keep.

What we can do is read your reports and say whether your diagnosis is even in a category where CAR-T is discussed, explain what the referral pathway would involve in practice, and give you a written second opinion on the treatment you have already been offered. Where a referral to a cell-therapy centre is the right next step, we will say so plainly.

The immunotherapy given as day care at CION centres is checkpoint-inhibitor treatment. It is a different class of medicine with a different side-effect pattern, and its immune-related reactions tend to build over weeks rather than arriving as the sharp early reaction seen after a CAR-T infusion. Response-assessment PET-CT during that treatment is coordinated at partner imaging centres rather than owned by CION.

• Indian-Made CAR-T vs Imported: Is There a Difference? — where the products differ, and where the monitoring and CRS protocols around them are the same.
• How Long Do CAR-T Responses Last? Honest Long-Term Outcomes — useful once the CRS window is behind you and the real question becomes what the months afterwards look like.
• Funding CAR-T: Insurance, Schemes and Assistance — the ICU days and toxicity medicines described on this page are part of the bill, so read it alongside the estimate.
• Immunotherapy at CION Cancer Clinics — the treatments CION does provide, how eligibility is assessed, and what a first consultation covers.

This page is general information and does not replace a consultation. CION Cancer Clinics does not provide CAR-T or any cell therapy and does not manage cytokine release syndrome after an infusion; immunotherapy at CION means checkpoint-inhibitor treatment given as day care, with response-assessment PET-CT coordinated at partner imaging centres. Any cost figure discussed anywhere is indicative, as of August 2026. Only your treating team, reviewing your complete case, can tell you what applies to you.

Most families hear about CRS long before they understand it

If someone in your family is being assessed for CAR-T, ask us what the weeks around the infusion really involve. You will get a straight answer.